A seroepidemiological study of naturally occurring antibodies to the human syncytial virus has been carried out by means of an indirect immunofluorescence test on 639 East Africans, consisting of 493 normal Ugandans, 66 Kenyan patients with nasopharyngeal carcinoma (NPC), and 80 Kenyan and Tanzanian patients with various other tumours or non-cancerous conditions. It was found that 3"4% of the normal individuals had antibodies to the virus and serial serum samples were available from I4 of these, permitting the study of antibody class in seroconversion and antibody persistence. As in an earlier survey, a significantly higher incidence of antibodies was found amongst NPC patients. Blocking and indirect immunofluorescence tests with simian foamy viruses (SFV) showed some cross-reactivity between SFV 6 and the human syncytial virus, but not identity. The results are discussed in relation to the very real occurrence of natural infection by human syncytial virus in certain geographical regions.
INTRODUCTION
In a preliminary seroepidemiological survey of naturally occurring antibodies to the human syncytial virus (Achong et al. 1971 ), a high incidence was found in Kenyan patients with nasopharyngeal carcinoma (NPC) (24 °K, ) and other tumours (except Burkitt's lymphoma, BL) and a lower but appreciable incidence (5%) in sera from a small sample of normal Kenyan individuals (Achong & Epstein, I978) . To explore further this natural infection by human syncytial virus amongst East Africans, sera from a much larger sample of normal individuals and cancer patients from Uganda, Kenya and Tanzania have been screened for specific antibodies to the virus using an indirect immunofluorescence test. Because the human syncytiaI virus had been found to have slight immunological relatedness to simian foamy virus (SFV) type 6 in earlier neutralization studies (Epstein et al. 1974) , blocking tests and tests for direct reactivity by antisera to various SFV have been included in the immunofluorescence experiments. The present paper reports the results obtained.
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METHODS
Cells. Whole human embryo fibroblasts (HEF) Flow 5ooo, obtained from Flow Laboratories (Irvine, Scotland), were used between the 2~st and 28th passages. The HEF were grown at 37 °C in plastic tissue culture flasks in Eagle's basal medium supplemented with io% foetal calf serum, I~ non-essential amino acids, o.o8% bicarbonate, Ioo units/ml penicillin and I oo/~g/ml streptomycin. When required, the cells were obtained in suspension by treating the cultures with o'o5 % trypsin and o.I % EDTA in phosphate-buffered saline (PBS).
Virus. Virus pools were prepared in 800 mI plastic tissue culture flasks by removing the medium from subconfluent HEF cultures and inoculating the monolayer cultures with 8 to IO ml of undiluted cells and medium from infected cultures (Epstein et al. I974) . After 3 h adsorption at 37 °C with intermittent shaking, 70 ml of fresh medium were added. When a good c.p.e. (Epstein et al. 1974 ) involving more than 8o % of the cells was observed, the infected cultures, both cells and medium, were harvested and stored in small volumes at -70 °C.
Preparation of infected HEF for immunofluorescence staining. HEF suspensions in medium (I to 2 ml), containing about 3'5 x lo ~ cells/ml were seeded into 6o mm plastic Petri dishes containing i6 mm diam. coverslips; 6 ml medium were added and the Petri dishes incubated at 37 °C. When the cells had grown evenly over the coverslips the medium was removed and I ml of virus pool was added. After gently rocking to distribute the inoculum evenly, the virus was allowed to adsorb at 37 °C for 3 h and 6 ml fresh medium were introduced. About 72 h after inoculation, the coverslips were removed, washed with PBS, fixed in cold acetone for Io min and, after checking under phase-contrast microscopy for virus-induced c.p.e., stored at -7o °C in sealed plastic bags.
Indirect immunofluorescence. Infected coverslip cultures, prepared as described above, were exposed to serum diluted 1:4 in PBS for I h at 37 °C in a moist chamber. The coverslips were then washed in PBS as previously described (Achong & Epstein, I978) and stained with ftuorescein isothiocyanate (FITC)-conjugated sheep anti-human immunoglobulin (fluorescein :protein molar ratio 3"7; Welleome Reagents Ltd., Wellcome Research Laboratories, Beckenham, Kent) diluted ~ : 2o in PBS. After incubation in a moist chamber for I h at 37 °C, they were washed in PBS as before, mounted on glass slides in a PBS/ glycerol (I:I) mixture and examined in a Leitz Photomieroscope II with a III RS attachment. The following controls were also included. 0) Positive serum controls: a human serum known to contain naturally occurring antibody to human syncytial virus (titre 1:64) was used at a dilution of I:I6. (2) Antigen controls: infected coverslip cultures incubated with PBS instead of positive serum and then fluorescent antibody, and uninfected coverslip cultures incubated with positive serum and then fluorescent antibody, served as antigen controls.
Human test sera. The following sera were examined: (i) 493 sera from clinically normal people in the northern part of the West Nile District of Uganda, some of which came from individuals from whom serial serum samples were available. The sera were obtained during the survey carried out by the International Agency for Research on Cancer 0972 to I976) and were provided by G. L. ; (ii) Io8 sera collected in Kenya and Tanzania during I97z to I975 by A. L. from 8o patients with BL, NPC and other tumours, and from 18 patients with non-neoplastic conditions; in this batch all the NPC patients were from Kenya; (iii) when it was found that the incidence of positive sera was somewhat lower amongst the Kenyan and Tanzanian cancer patients in the present study than had been observed earlier in Kenyan cancer patients (Achong & Epstein, ~978) further sera from Human syncytial virus in East Africa 4Ol Kenya (97; 1972-75) and Tanzania (I I ; 1972-75) (c) Kenya (38; 1968-73) 38 Kenyan NPC cases from the Kenyatta National Hospital, Nairobi were investigated. These sera were kindly provided by Professor George Klein (Department of Tumor Biology, Karolinska Institut, Stockholm, Sweden) and had been taken at about the same time (I968 to r973) and in the same hospital as those studied previously (Achong & Epstein, I978) .
Tests for antibody class in positive sera. Of the positive sera, those for which serial samples were available were investigated to determine the class of antibody in each sample. Virusinfected HEF were exposed to the test serum diluted 1:4 in PBS for i h at 37 °C as described above and thereafter to monospecific FITC-conjugates of sheep antisera to human IgG, IgM and IgA (Wellcome Reagents Ltd.). The conjugates were used at a dilution of I:2o in PBS and their fluorescein to protein molar ratios were as follows: anti-IgG, 3.25; anti-IgM, 4"I ; anti-IgA, 4"o.
Cross-reactivity tests between human syncytial virus and simian foamy viruses (SFV)
Blocking tests. Coverslip preparations of virus-infected HEF were treated with rabbit antiserum to SFV 6 (Johnston, I97I) diluted 1:4 in PBS, followed by a human serum (diluted I : I6) known to react to the human syncytial virus at a titre of 1:64 in the indirect immunofluorescence test; the test was completed by adding FITC-conjugated sheep antihuman immunoglobulin. Each serum was allowed to react at 37 °C for I h, and the preparations were washed in PBS after each reaction in the usual way. Rabbit antiserum to SFV 3 (Johnston, I97I) and normal rabbit serum were used as negative controls.
Immunofluorescence tests. Coverslip preparations of virus-infected HEF were treated either with rabbit antiserum to one of four SFV (3, 5, 6 or 7) (Johnston, ~97I) at dilutions of 1:4 and I:8, or with normal rabbit serum, saline or rabbit antiserum to the human syncytial virus (Loh et al. I977) diluted I:8. After this, the cells were washed as usual and then exposed to FITC-conjugated goat antiserum to rabbit immunoglobulin (kindly supplied by Dr J. R. North, Department of Pathology, University of Bristol) in the usual way. All the antisera to SFV were kindly supplied by Dr P. B. Johnston, University of Louisville, Kentucky, U.S.A.
RESULTS
Positive sera gave an intense, finely granular cytoplasmic fluorescence of the multinucleated syncytial cells exactly as in earlier work (Achong & Epstein, I978) . The incidence of antibodies to the human syncytial virus in East African populations is summarized in Table I . It is evident that 3"4 % of nearly 5oo normal Ugandans had antibodies to the I4 VIR 47 virus ( Table I a) and that, in contrast, amongst the first small group of Kenyan patients with NPC, 7.1% were antibody-positive (Table ~ b) . Although the numbers were likewise small, with other disease categories, no specific antibodies were detected in the sera of patients from Kenya and Tanzania with non-neoplastic conditions, other tumours and BL; this negative finding with BL matches that from another small group of Kenyan BL patients reported earlier (Achong & Epstein, 1978) . Details of the seropositive normal Ugandans from whom serial serum samples were available, are shown in Table 2 . In six of these, the initial sera were negative and subsequently became positive and in one such case (MW o9o) the antibody titre increased over a period of 29 months. Another individual in this group (AF 219) was unusual in that although the first serum sample was negative and the second positive, the third sample taken 6 months later was negative, while a fourth sample obtained after a further 9 months was again positive. These apparent changes in seropositivity probably reflect fluctuations in low levels of antibody around the minimum titre adopted in the present experiments as positive (1:4).
Two normal donors (PJ 972, AA 92I) who were positive when first sampled were subsequently found to be negative 8 and ~ I months later, respectively.
Antibodies were not detected before the age of 3 years (5o sera from children of o to Human syncytial virus in East Africa 403 3 years were examined), the oldest individual with antibodies (SA 238 ) was aged 75, and there was no sex difference in antibody incidence ( Table 2 ). The highest titre detected (I : 32) was in the serum of a 4o-year-old male from whom only one sample was available. The incidence of antibodies in the second group of Kenyan NPC patients (Table I c) was 8"4 %, considerably higher than the incidence in the first group of NPC patients shown in Table I b. Individual titres in the second group ranged from I :4 to i: 32 and the age distribution of the seropositives was between 23 and 47 years. It is important to note that all the positive NPC patients in both the first and the second groups were sampled during or before 1973.
With regard to the antibody class present in the seropositive individuals with more than one serum sample available for testing (Table 2) In blocking tests to assess possible cross-reactivity between the human syncytial virus and SFV 6 it was found that when rabbit antiserum to SVF 6 was applied to cells infected with human syncytial virus before testing with high titre human antiserum to the human virus, no blocking effect was demonstrated as compared to control rabbit sera (normal or antiserum to SFV 3). On the other hand, when various rabbit antisera to SFV were applied to cultures infected with human syncytial virus some weak cross-reactivity with SFV 6 and SFV 7 was observed; this cross-reaction with SFV 6 matched well that reported earlier in neutralization tests (Epstein et al. I974 ).
DISCUSSION
The 3"4 % incidence of antibodies to human syncytial virus detected in a large group of normal Ugandans in the present survey is of the same order as that reported in an earlier preliminary study (Achong & Epstein, 1978) where only 19 normal sera were available. In view of the size of the sample of normal individuals examined here (493; Table I a) it is evident that a low incidence of infection by the human syncytial virus is a real phenomenon in East Africa and it is very significant that a second geographical area of infection, in the Pacific, has recently been reported (Loh et aL I979) . The presence of uniformly negative results from several populations in the preliminary survey (Achong & Epstein, I978) and the failure of absorption of positive sera with IgG-coated Sepharose to reduce antibody titres to the human syncytial virus, make it clear that the immunofluorescence test used for such antibodies did not give false-positive results.
In the present East African survey antibodies first appear in individuals aged about 3 years and may be detected in those as old as 75; from the evidence of seroconversions amongst individuals from whom serial serum samples were available (Table 2) , it is clear that infection can take place at any age and this group of serially bled individuals has also shown that the antibodies may persist for long periods ( Table 2 ). The antibody titres obtained in the present survey, with a maximum of I : 32, are of the same order as those reported previously (Achong & Epstein, 1978) and those found in the Pacific study (Loh et aL 1979 
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The results from serum donor AF 2I 9 are particularly interesting: not only did this individual show low fluctuating levels of antibody to the human syncytial virus (Table 2) , but in parallel she also showed unusual serological responses to Epstein-Barr (EB) virus. The EB virus profile (G. Lenoir, unpublished data) was similar to that seen in the rare cases of defective immune response to this infection, that is high anti-VCA associated with low anti-EBNA titres (Berkel et al. I979) . Indeed, one serum sample from AF 2I 9 was actually negative for EBNA antibodies, a very unusual finding in East African populations (de-Th6 et al. I978), and it would appear that this individual's poor responses to the human syncytial virus and EB virus are both aspects of the same general immunological deficiency.
It is also of interest that of the I4 cases analysed in detail in Table 2 , two young individuals (PJ 972 and AA 92I) became seronegative 8 and 11 months, respectively, after they were first found to have antibodies to the human syncytial virus. This change in serological status probably reflects the termination of an episode of active infection by the virus.
Of the patients with tumours, antibodies to human syncytial virus were only detected in those with NPC (Table t b, c) , which is in contrast to the earlier finding (Achong & Epstein, I978) where about 2o % of 28 patients with tumours other than NPC had antibodies to the virus. Furthermore, the 7:I % antibody incidence in one group of East African NPC patients in the present survey (Table I b) is substantially below the 24 % incidence found earlier for such patients from Kenya (Achong & Epstein, I978) . However, careful review of the dates of bleeding of the East African NPC patients with antibodies to the human syncytial virus indicated that both seropositive patients in the first group of the present survey (Table I b) had been bled in I973 whereas the seronegative NPC patients were all bled later; similarly, all Io seropositive NPC patients of the earlier survey (Achong & Epstein, I978) were also bled before or during I973. It was because of these findings that a further set of sera from Kenyan NPC patients bled in the years up to 1973 was obtained from Professor Klein. All the seropositives in this second group (Table 1c) were again found amongst those bled before or during 1973 and the incidence rate of antibodies (18"4%; Table I c) was of the same order as that found in the earlier survey (24%; Achong & Epstein, I978) . It would appear that considerable infection with the human syncytial virus prevailed in Kenya in the years up to and including I973 and that this in some way affected NPC patients to an unusual extent. This could have resulted from the tumour condition itself or, as seems more likely, from some local outbreak of infection at the time in question in those high and cold regions of Kenya where NPC is prevalent (Clifford, 197o) .
There is certainly no indication that NPC patients in general are especially susceptible to infection by human syncytial virus, since antibodies to the virus have not been found in sera from such patients from Tunisia, Singapore (Achong & Epstein, 1978) It has been suggested on the basis of antigenic characteristics that the human syncytial virus is a variant of SFV 6 (Nemo et al. I978) and even that it 'represents either the chance infection of a human with a simian foamy virus or the unfortunate discovery of a laboratory contaminant'. As regards the latter possibility it should be stressed yet again that the original virus-yielding NPC biopsy had been grown up to the time of virus isolation only in human serum and without the addition of any other cells (Achong et al. I97I) , thus excluding the inadvertent introduction of an animal foamy virus. Furthermore, the preliminary seroepidemiological studies reported earlier (Achong & Epstein, t978) showed naturally occurring antibodies to the virus in East African sera on a sufficient scale to make 'chance infection of a human with a simian foamy virus' an unlikely explanation for the association of the virus with human material. The present much larger scale survey of sera from East Africa now provides solid confirmatory evidence for an appreciable level of natural infection by the virus in normal populations from Uganda (Table I) , confirms a higher incidence of antibodies to the virus in East African patients with NPC (Table I b, c) and suggests that considerable infection by the virus appears to have occurred in the years just before and including 1973. Finally, reports of further isolations of syncytial viruses coming directly from human material have recently appeared (Cameron et aI. I978; Werner & Gelderblom, T979) and, more importantly, there is now conclusive evidence for the presence of naturally occurring antibodies to the human syncytial virus in nine different Pacific Island territories, where there are certainly no simian populations; in this latter survey I717 sera were examined with an average prevalence of antibodies of 6"9 °fo (Loh et al. I979) .
Some degree of relatedness between the human syncytial virus and both SFV 6 and bovine syncytial virus has already been reported (Epstein et al. I974) and further confirmation in the case of SFV 6 (Nemo et aL I978 and the present study) is not therefore surprising. However, it should not be forgotten that antigenic relationships need not indicate identity. For example, cross-reactivities are known to occur between EB virus and the gammaherpesviruses of Old World primates; all members of this group of agents share common antigens but, on the other hand, have only rather limited genome homology (Deinhardt & Deinhardt, t979) . Thus, the human syncytial virus, in spite of some relatedness to SFV 6, must be considered a distinct human agent with specific geographical regions of naturally occurring infection. This work was assisted by the Cancer Research Campaign, London, England, out of funds donated by the Bradbury Investment Co. of Hong Kong. One of us (H. K. M.) was on sabbatical leave from Monash University, Melbourne, Australia. The authors are most grateful to Miss Colette Bonnardel for invaluable help.
